Respiratory
Latest news
198 articles · 20 / page
Simplifying Pulmonary Embolism Exclusion: Can One Clinical Question Safely Reduce Imaging?
A prospective multicenter study demonstrates that using a single clinical question—whether pulmonary embolism is the most likely diagnosis—to adjust D-dimer thresholds can safely reduce chest imaging by 19% in emergency departments without
Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC
The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m
Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial
The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.
Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, an
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression
Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies
This article synthesizes recent findings on the KRAS G12V mutation in non-small cell lung cancer, highlighting its unique molecular profile, strong association with smoking, and superior response to immunotherapy compared to traditional che
Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI
This phase 1 trial identifies APG-2449 as a potent ALK/ROS1/FAK inhibitor. It shows significant efficacy in TKI-naïve and second-generation TKI-resistant ALK+ NSCLC, with high blood-brain barrier penetration and a manageable safety profile,
Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial
The final analysis of the Phase III ALEX trial confirms alectinib’s superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the first-lin
The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps
A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a
Awake Prone Positioning in COVID-19 Respiratory Failure: A Synthesis of Clinical Trial Evidence and the PROVID Study
This review synthesizes the findings of the PROVID randomized clinical trial and broader literature, demonstrating that awake prone positioning (APP) significantly reduces the probability of intubation and death in patients with COVID-19 hy
Early CPAP Intervention May Mitigate Parkinson Disease Risk in Patients with Obstructive Sleep Apnea
A massive cohort study of 11.3 million US veterans reveals that obstructive sleep apnea is an independent risk factor for Parkinson disease, but early treatment with CPAP significantly reduces this risk, particularly in women.
Durability and Decay: Evaluating Long-term RSV Vaccine Effectiveness in a Large Real-World Cohort of US Veterans
This review analyzes the long-term effectiveness of RSV vaccination among US Veterans, revealing significant protection against severe outcomes that wanes over two seasons, particularly in immunocompromised populations.
Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk
Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p
Combined Multiplex PCR and Procalcitonin Strategy Fails to Increase Antibiotic-Free Days in Critically Ill Patients with CAP: Insights from the MULTI-CAP Trial
The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative d
Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
Inflammatory Subphenotypes in COVID-19 ARDS Exhibit High Temporal Stability: Insights from the ICAR Trial
A reanalysis of the ICAR trial reveals that ARDS inflammatory subphenotypes remain remarkably stable over 28 days. The hyperinflammatory profile is linked to higher mortality and distinct biomarkers, with Bayesian modeling showing minimal t
Dynamic Phenotyping in ARDS: AI-Driven Insights Reveal Why Corticosteroid Benefits Depend on Inflammatory State
A groundbreaking study utilizing an AI classifier demonstrates that ARDS inflammatory phenotypes are dynamic and dictate corticosteroid efficacy. While hyperinflammatory patients benefit from steroids, hypoinflammatory patients face increas
Beyond a Marker of Severity: Reaffirming the Impact of Ventilator-Associated Events on Mortality
A rigorous multicenter study from Japan utilizes marginal structural modeling to demonstrate that Ventilator-Associated Events (VAEs) are independent drivers of mortality, not just surrogates for patient severity, reinforcing their value as
Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial
The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective o
Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study
A randomized trial demonstrates that a smartphone app-based pulmonary rehabilitation program significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable alternative to trad
Browse by specialty
Open language-specific specialty feeds and department pages.